Ayrton Capital Llc Opened Huge Delcath Systems, Inc Position

February 14, 2018 - By Stephen Andrade

 Ayrton Capital Llc Opened Huge Delcath Systems, Inc Position

The New Ayrton Capital Llc Holding in Delcath Systems, Inc

Ayrton Capital Llc reported SC 13G form with the SEC for Delcath Systems, Inc. Access it here: 000114420418008046. As reported by Ayrton Capital Llc, the filler owns 7.1% or 30,860,000 shares of the Health Care–company.

Delcath Systems, Inc stake is new for [reportingPerson]. Date of activity: February 9, 2018. This shows Ayrton Capital Llc’s positive view for Delcath Systems, Inc.

Delcath Systems, Inc Institutional Sentiment

Filings show 22 investors own Delcath Systems, Inc. The ownership in Q3 2015 is low, at Infinity of the outstanding shares. This is increased by 4880230. 6450954 were owned by these investors. 5 funds opened new Delcath Systems, Inc stakes, 4 increased positions. There were 6 that closed positions and 4 reduced them.

Brookstone Capital Management is an investor bullish on Delcath Systems, Inc, owning 240 shares as of Q3 2015 for less than 0.01% of its portfolio. Vanguard Group Inc owns 4485838 shares or 0.01% of its portfolio. NY Allsquare Wealth Management Llc have less than 0.01% of its portfolio for 125 shares. Further, Private Advisor Group Llc reported stake worth 0.01% of its portfolio. The NY Cowen Group Inc owns 486300 shares. Delcath Systems, Inc is 0.01% of its portfolio.

Business Profile

Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company’s system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company’s focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.

SEC Form 13G.

The stock decreased 1.67% or $0.0005 during the last trading session, reaching $0.0295. About shares traded. Delcath Systems, Inc. (OTCMKTS:DCTH) has declined 99.33% since February 14, 2017 and is downtrending. It has underperformed by 116.03% the S&P500.

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company has market cap of $6.58 million. The firm is developing melphalan hydrochloride for Injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. It currently has negative earnings. It offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe.

More notable recent Delcath Systems, Inc. (OTCMKTS:DCTH) news were published by: Seekingalpha.com which released: “Delcath: It Is All About Survival” on September 06, 2017, also Globenewswire.com with their article: “Delcath Systems, Inc. Announces Extension of Expiration Date of its Consent …” published on August 22, 2017, Seekingalpha.com published: “Delcath Systems Offers Significant Upside For Risk-Tolerant Investors” on July 10, 2017. More interesting news about Delcath Systems, Inc. (OTCMKTS:DCTH) were released by: Seekingalpha.com and their article: “Delcath Systems: Wait For The Dust To Settle” published on July 07, 2017 as well as Seekingalpha.com‘s news article titled: “Delcath: Massive Dilution Ahead” with publication date: July 28, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.